Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P
Medtronic, Inc. · Decision date Oct 5, 2026
What did the FDA decide?
The FDA record lists PMA supplement P010015/S590 for the Percepta and Serena bipolar and quadripolar CRT-P and Solara bipolar CRT-P devices, with an OK30 decision dated 2026-10-05. The supplement is a 30-Day Notice filed under process change for manufacturer, sterilizer, packager or supplier, and the stated purpose is process and equipment updates in the manufacturing of MR Delta 26H3 batteries used in Medtronic CRM devices.
The identifier ties S590 to the original P010015 approval, so this is a supplement to that file rather than a separate approval of the full system. The notice covers the battery manufacturing step described in the statement; it does not set out which process parameters or equipment changed, any supporting data, or the basis for the decision, and it is not independent proof of safety or clinical effectiveness.
FDA approval order statement
process and equipment updates of the manufacturing process of MR Delta 26H3 batteries used in Medtronic CRM devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 5, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010015/S590
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- Decision code
- OK30
- Decision date
- Oct 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010015 · Original PMA
MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM
P010015/S590 received
Application receipt date recorded by FDA.
P010015/S590 · FDA decision
30-Day Notice
P010015/S591 · Related supplement
Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar
P010015/S592 · Related supplement
Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P
Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Aug 28, 2001 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA approval | Apr 25, 2016 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010015/S590
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

